M de Boer-Dennert

1.7k citations

30 papers · 1.5k indexed · h-index 18

Co-authors: Jaap Verweij G. Stoter Ronald de Wit V van Beurden Hilde Rosing Jan H.M. Schellens JHM Schellens A.S.T. Planting
Topics: Cancer therapeutics and mechanisms (15 papers)Neutropenia and Cancer Infections (10 papers)Lung Cancer Research Studies (8 papers)
Cited by: Oncology Toxicology Molecular Biology
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute British Journal of Cancer
Partner nations: Netherlands United States Denmark

In The Last Decade

M de Boer-Dennert

30 papers receiving 1.4k citations

Peers

Countries citing papers authored by M de Boer-Dennert

Since Specialization

Citations

This map shows the geographic impact of M de Boer-Dennert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M de Boer-Dennert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M de Boer-Dennert more than expected).

Fields of papers citing papers by M de Boer-Dennert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M de Boer-Dennert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M de Boer-Dennert. The network helps show where M de Boer-Dennert may publish in the future.

Co-authorship network of co-authors of M de Boer-Dennert

This figure shows the co-authorship network connecting the top 25 collaborators of M de Boer-Dennert. A scholar is included among the top collaborators of M de Boer-Dennert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M de Boer-Dennert. M de Boer-Dennert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in diagnostic and treatment strategies of oesophageal cancer in the period from 2001 to 2009 2011 ·European Journal of Gastroenterology & Hepatology ·Marjolein Y.V. Homs,Martijn G.H. van Oijen,Bas P. L. Wijnhoven,Richard van Hillegersberg,M de Boer-Dennert,Peter D. Siersema	6
2	Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer 2003 ·British Journal of Cancer ·Jan H.M. Schellens,André Planting,Nico van Zandwijk,Jun Ma,Marc Maliepaard,M.E.L. van der Burg,M de Boer-Dennert,E. Brouwer,Ate van der Gaast,Martin J. van den Bent,Jaap Verweij	11
3	The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study 1999 ·Cancer Chemotherapy and Pharmacology ·L. Pronk,Wim L.J. van Putten,V van Beurden,M de Boer-Dennert,G. Stoter,Jaap Verweij	4
4	Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists 1997 ·British Journal of Cancer ·M de Boer-Dennert,Ronald de Wit,(unknown),(unknown),V van Beurden,G. Stoter,Jaap Verweij	301
5	The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor 1997 ·British Journal of Cancer ·(unknown),JHM Schellens,G.J. Creemers,Paul Wissel,A.S.T. Planting,J. Fred Pritchard,(unknown),M de Boer-Dennert,Miranda Harteveld,Jaap Verweij	24
6	Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor 1996 ·British Journal of Cancer ·JHM Schellens,G.J. Creemers,Jos H. Beijnen,Hilde Rosing,M de Boer-Dennert,Mirna McDonald,B. E. Davies,Jaap Verweij	113
7	Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure 1996 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Geert‐Jan Creemers,Sjoerd Rodenhuis,Hilde Rosing,M de Boer-Dennert,Jan H.M. Schellens,W.W. ten Bokkel Huinink,Brian E. Davies,R. A. A. Maes,Jaap Verweij,Jos H. Beijnen	32
8	Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours 1996 ·British Journal of Cancer ·JHM Schellens,Jun Ma,A.S.T. Planting,(unknown),E. van Meerten,M de Boer-Dennert,(unknown),G. Stoter,Jaap Verweij	122
9	Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. 1996 ·Journal of Clinical Oncology ·Ronald de Wit,P.I.M. Schmitz,Jaap Verweij,M de Boer-Dennert,(unknown),A.S.T. Planting,M E van der Burg,G. Stoter	37
10	Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration 1996 ·British Journal of Cancer ·(unknown),G.J. Creemers,JHM Schellens,Paul Wissel,(unknown),Robert L. Kunka,(unknown),M de Boer-Dennert,(unknown),Miranda Harteveld,Jaap Verweij	37
11	Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets 1996 ·British Journal of Cancer ·Ronald de Wit,(unknown),Olaf van Tellingen,JHM Schellens,M de Boer-Dennert,Jaap Verweij	10
12	Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma 1996 ·European Journal of Cancer ·A.S.T. Planting,(unknown),S.H. Goey,Jan H.M. Schellens,Ch.J. Vecht,M de Boer-Dennert,G. Stoter,Jaap Verweij	7
13	Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer 1996 ·British Journal of Cancer ·(unknown),(unknown),Martin J. van den Bent,M de Boer-Dennert,G. Stoter,Jaap Verweij	16
14	Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair 1995 ·British Journal of Cancer ·Jun Ma,Jaap Verweij,A.S.T. Planting,M de Boer-Dennert,(unknown),(unknown),G. Stoter,JHM Schellens	29
15	Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors 1995 ·Annals of Oncology ·André Planting,M E van der Burg,M de Boer-Dennert,G. Stoter,Jaap Verweij	16
16	Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks 1995 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Jaap Verweij,Jan H.M. Schellens,Hilde Rosing,Brian E. Davies,M de Boer-Dennert,R. A. A. Maes,J. H. Beijnen	84
17	Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma 1995 ·Annals of Oncology ·André Planting,(unknown),S.H. Goey,(unknown),Martin J. van den Bent,M de Boer-Dennert,G. Stoter,Jaap Verweij	34
18	Weekly high-dose cisplatin in malignant pleural mesothelioma 1994 ·Annals of Oncology ·André Planting,Jan H.M. Schellens,S.H. Goey,M.E.L. van der Burg,M de Boer-Dennert,G. Stoter,Jaap Verweij	38
19	Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours 1993 ·British Journal of Cancer ·(unknown),(unknown),M de Boer-Dennert,G. Stoter,Jaap Verweij	29
20	Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor 1993 ·Annals of Oncology ·Jaap Verweij,Birthe Lund,Jos H. Beijnen,(unknown),M de Boer-Dennert,(unknown),Hilde Rosing,H. Hansen	110

About M de Boer-Dennert

M de Boer-Dennert is a scholar working on Oncology, Toxicology and Statistics and Probability, having authored 30 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (15 papers), Neutropenia and Cancer Infections (10 papers) and Lung Cancer Research Studies (8 papers). The work is most often cited by research in Oncology (806 citations), Toxicology (61 citations) and Molecular Biology (627 citations). M de Boer-Dennert has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Jaap Verweij, G. Stoter, Ronald de Wit, V van Beurden, Hilde Rosing, Jan H.M. Schellens, JHM Schellens, A.S.T. Planting, Jos H. Beijnen and André Planting. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact